ContraFect Corporation (CFRX) has been one of the most talked-about biotech stocks in the market, especially in the last few months. The company focuses on developing novel therapeutics for infectious diseases, using its cutting-edge platform technology, which targets low-lying bacteria. They have devoted themselves to improving patient care and offering alternative, efficient therapies for antibiotic-resistant bacterial infections.
There has been rampant speculation about CFRX because the stock price has experienced a significant increase recently. In December 2019, CFRX was trading at $1.79, and as of June 16th, 2021, the price was $6.05, an increase of 236%. This increase has undoubtedly caught the attention of potential investors, but what could have brought about the bullish trend? Let’s take a deep dive into CFRX’s latest developments and what could drive the stock price further up.
Game-Changing FDA News
The Food and Drug Administration (FDA) is the regulatory body that oversees drug approvals in the US. ContraFect Corporation has been waiting for news from the FDA regarding an investigational new drug application (IND) for CF-370, a therapy that targets Staphylococcus aureus (STAPH), a notoriously antibiotic-resistant bacterium. On June 15th, 2021, the company announced that it had received authorization from the FDA to proceed with its IND application for CF-370.
This news is significant for the company because the primary focus has been on the development of CF-370 for the last couple of years. If clinical trials are successful, CF-370 will be the world’s first biobetter that can target the main strain of antibiotic-resistant STAPH. The drug’s potential to revolutionize the treatment of hospital-acquired infections, which account for many deaths every year, cannot be understated. The news of the IND authorization creates a positive outlook for CFRX and is likely to increase investor confidence in the company’s future prospects.
CFRX’s Innovative Science Platform
ContraFect Corporation’s platform technology represents a significant advantage for the company in the highly competitive biopharmaceutical industry. Their lysin technology is highly effective in targeting bacteria that are resistant to traditional antibiotic therapies. The lysins’ mode of action enables a precise attack on the bacterial cell wall, leaving the surrounding human tissues and microbiome intact.
The company has a history of successes with its science platform. For example, in a Phase 2 clinical trial, the company’s drug candidate, Exebacase, successfully treated patients with Staphylococcus aureus bacteremia. Patients who received Exebacase reportedly had a higher survival rate than patients treated with a standard-of-care antibiotic. The results put CFRX in an excellent position to further develop their platform technology.
FDA Pressure On Antibiotic-Resistant Infections
Antibiotic resistance to infectious diseases is a growing concern for health institutions globally. The World Health Organization warns that there is a clear danger of returning to a time when common infections came with a relatively high risk of death.
The US Government, through the Federal Action Plan for Combating Antibiotic-Resistant Bacteria, has identified antibiotic resistance as one of its highest public health priorities. They have introduced programs such as the AMR Challenge, intended to reduce the emergence and transmission of antibiotic-resistant infections. This level of focus on the issue by the FDA and the government is favorable for CFRX. As such, the industry could see increased funding, research programs, and drug approvals, driving the stock price higher.
CF-370 Business Potential
CF-370 represents a highly promising treatment option for many infections caused by STAPH, including but not limited to pneumonia, skin infections, and bone/joint infections. By targeting the STAPH bacterium that accounts for many healthcare-associated infections, ContraFect Corporation aims to offer an efficient means of reducing related deaths and hospitalization costs. The company has the potential to build a product portfolio from their lysin technology, thereby increasing revenue streams.
The future of this line of business is highly promising, and stakeholders are certainly taking note of the latest developments. A successful approval and market launch of CF-370 will likely increase investor trust in CFRX, driving the stock price further up.
Is CFRX a good investment?
ContraFect Corporation’s stock price has increased by over 200% in 18 months. This increase in price is due to several factors, including innovative science, regulatory news, and the pandemic’s current health care focus on infectious disease control. With the FDA’s latest approval, the company has the potential to develop new therapies to target antibiotic-resistant infections. The success of the platform technology in clinical trials and CF-370’s development bodes well for CFRX’s future.
The increase in demand for antibiotics and antimicrobial resistance procedures is likely to continue to create tailwinds for the company over the next few years, thereby contributing to the upswing in stock rates. While the market is undecided in its reaction, we welcome the prospect of a continued bullish trend for ContraFect Corporation’s stock price as it continues its work towards providing an accessible means of improving patient care for infectious diseases.